Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6107976 | 0.91 | F10 (0.86) | F10KCNH2KLKB1TP53TSHR | |
| SCHEMBL2431134 | 0.90 | F10 (1.00) | F10KCNH2KLKB1 | |
| SCHEMBL12326305 | 0.90 | F10 (0.80) | F10KCNH2KLKB1TP53TSHR | |
| SCHEMBL12325912 | 0.90 | F10 (0.86) | F10KCNH2KLKB1 | |
| SCHEMBL6108061 | 0.88 | F10 (0.77) | F10KCNH2KLKB1 | |
| SCHEMBL2436470 | 0.88 | F10 (0.77) | F10KCNH2KLKB1TP53TSHR | |
| SCHEMBL12326033 | 0.88 | F10 (0.83) | F10KCNH2KLKB1 | |
| SCHEMBL2431090 | 0.88 | F10 (0.83) | F10KCNH2KLKB1 | |
| SCHEMBL6111272 | 0.86 | F10 (0.73) | F10KCNH2KLKB1 | |
| SCHEMBL799840 | 0.84 | F10 (1.00) | F10KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708265-B2 | Urethanes, ureas, amidines and related inhibitors of factor Xa | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2017-07-18 | — | — | US | disclosed |
| EP-2542529-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | Tovbin, Dmitry Gennadievich (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PHARMADIALL LIMITED LIABILITY COMPANY (RU) | 2013-01-03 | — | — | US | disclosed |
| WO-2011108963-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | TOVBIN DMITRY GENNADIEVICH (RU) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005778-A1 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA | PLAUR, PLAU, UTS2R | F10 9/4885KCNH2 1486/4885KLKB1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.